Novartis, Bristol Myers Squibb pause CAR-T trials for lupus and other autoimmune diseases for safety reviews
Novartis and Bristol Myers Squibb paused CAR-T trials for autoimmune diseases due to safety concerns. Novartis halted rap-cel trials after three deaths from IEC-HS. Bristol Myers paused zola-cel enrollment after transient inflammatory events. Both companies are reviewing data with regulators.
How this was made
The 30-second read
Why it matters
Both companies face immediate share‑price pressure as investors reassess the risk profile of their CAR‑T pipelines, which are key growth drivers.
Market read
Safety pauses in high‑profile CAR‑T trials are material events for the companies involved and can trigger short‑term sell‑offs in biotech‑focused portfolios.
What to watch
Potential for accelerated regulatory dialogue or redesign of the trial could mitigate long‑term impact.
Background
The article reports the first public announcement that Novartis and Bristol Myers Squibb have halted enrollment in their respective CAR‑T programs for autoimmune diseases due to safety concerns.
Ticker impact
Novartis paused its rap‑cel CAR‑T trials for lupus and other autoimmune diseases after three participants suffered a fatal inflammatory syndrome.
likely pressure as investors price in safety concerns and potential delays.
First report of fatal events in the trial; market typically reacts negatively to safety holds on high‑profile biotech programs.
Bristol Myers Squibb voluntarily paused enrollment in its zola‑cel CAR‑T trials for autoimmune diseases after observing transient inflammatory events.
likely pressure as the market assesses risk to the CAR‑T pipeline.
First disclosure of a pause; investors treat trial suspensions as a negative catalyst for biotech stocks.
Market effects
CAR‑T and broader biotech sector may see heightened scrutiny and short‑term volatility.
US biotech indices could dip as two large caps face trial holds.
Limited to investors tracking major pharma pipelines; no broader macro effect.
Counterpoint
If the safety issues are isolated, the pause could be a short‑term overreaction and present a buying opportunity.
Key entities
- CompanyNovartis
Swiss pharmaceutical giant developing rap‑cel CAR‑T therapy.
- CompanyBristol Myers Squibb
US pharma company developing zola‑cel CAR‑T therapy.
